NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation...

NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of...

NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System LOS ANGELES, Sept. 27, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced that the Centers for Medicare & Medicaid Services ("CMS") has confirmed...

NeuroSigma Receives Bridge Financing from Checkmate Capital To Support Targeted Commercialization and Global Partnering of FDA-Approved Non-Drug Treatment for Pediatric ADHD LOS ANGELES, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. (“NeuroSigma”),...